Gilead Sciences, Inc. (GILD)

69.56
NASDAQ
Prev Close 69.67
Day Low/High 69.31 / 70.46
52 Wk Low/High 56.56 / 73.34
Exchange NASDAQ
Shares Outstanding 1254.38B
Market Cap 87.39B
P/E Ratio 68.31
Div & Yield N.A. (N.A)
Don’t Give Up On Gilead Sciences

Don’t Give Up On Gilead Sciences

The biotech juggernaut still has a lot going for it, especially at these levels.

Closing Bell: Airlines Rally on Deutsche Bulls; U.S. Stocks at Records

Closing Bell: Airlines Rally on Deutsche Bulls; U.S. Stocks at Records

An earlier rally lasted through the afternoon, pushing the S&P 500 and Dow Jones Industrial Average to close at fresh records.

Gilead's Major Trend Is Still Down

Gilead's Major Trend Is Still Down

Each bounce in the stock has been followed by a move to lower lows.

Biotechs and Builders Will Rock 2Q Earnings

Biotechs and Builders Will Rock 2Q Earnings

A look at who will be up and who will down this earnings season.

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.

Biogen: Quality at a Discount

Biogen: Quality at a Discount

Biotechs now offer some great valuations, and BIIB is prime example.

Getting Inside the Accounting at Gilead, Sirius and Netflix

Getting Inside the Accounting at Gilead, Sirius and Netflix

Focusing on whether or not a company's quarterly earnings beats Wall Street's analyst consensus is a foolish game.

My Takeaways and Observations

My month was made by Double D's comments, and I mean it.  At my core I am a softie, and D's sweet words tugged at my heart. I shared them with my family. Bottom line to me on the markets: This week's events reset global economic and profits growth l...

8 Beaten-Down Post-Brexit Bargains

8 Beaten-Down Post-Brexit Bargains

These names are now oversold and are sitting at attractive prices.

Gilead Downside Is Path of Least Resistance

Gilead Downside Is Path of Least Resistance

A new low down at $80 might be just enough weakness to prompt further declines.

3 Finds in Biotech's 'Pocket of Value'

3 Finds in Biotech's 'Pocket of Value'

Large biotech stocks are still at their cheapest valuations since 2011.

Cramer: Here's What's Really Behind This Hatred for Biotechs

Cramer: Here's What's Really Behind This Hatred for Biotechs

This is the group that is the most dangerous politically.

Takeaways and Observations

My thanks to James Gentile for substituting for me yesterday. Here are my takeaways and observations from yesterday's session: It was Groundhog Day on Wall Street again. We finished down, but well off of the session lows. I did no trading. The U.S. ...

My Latest Trades

Here's a rundown of the trades that I've made so far this morning: I sold my SPY June $208 puts at breakeven a few minutes ago. There are only two weeks left until this put expires, so I'm moving on. I've liquidated the balance of my four-stock biot...

Investors Ignoring Gilead Are on Drugs

Investors Ignoring Gilead Are on Drugs

This well-managed biotech company is trading for its lowest price/earnings multiple ever.

My Morning Musings

Phil (played by Bill Murray): What would you do if you were stuck in one place and every day was exactly the same, and nothing that you did mattered? Ralph: That about sums it up for me. -- Groundhog Day Wednesday was a relatively uneventful trading...

My Takeaways and Observations

Venezuela is the new Greece.  Icahn goes for some Allergan (AGN) -- a name of mine -- but his impact is muted after missteps in the energy space and elsewhere.   Nobody likes short people,  but I grow shorter daily. (Note: We got little hands and li...

If You Like Watching Paint Dry, Today's Your Day!

Here are random observation on a day that was like watching paint dry! Bonds are near the day's high, with iShares 20+ Year Treasury Bond ETF (TLT) up 75 cents, and bank stocks are near the day's lows. Limited volatility along most industry sectors ...

Jim Cramer: Wall Street Doesn’t Like Gilead

Jim Cramer: Wall Street Doesn’t Like Gilead

Jim Cramer says Gilead Sciences is a fine company, but doesn't have many fans on Wall Street.

Adding to a Quintet of Longs

I am back buying Hartford Financial Services Group (HIG) and the four members of my Biotech Basket -- Allergan (AGN), Intrexon (XON), Gilead Sciences (GILD) and Celgene (CELG).

My Takeaways and Observations

The day started with the challenges in the sneaker field.  Bloomberg on Goldman Sachs and Morgan Stanley analysts' Tesla (TSLA) price target hikes -- I believe (and am quoted) that these moves go against the spirit of the law.    I remember CNBC's M...

Today's Trades

Here's a recap what I've done so far today: I added to my longs of Hartford Financial (HIG) and Oaktree Capital (OAK). I substantially increased my short of the Consumer Staples Select Sector SPDR ETF (XLP), which is our Short Trade of the Week. I i...

Is Biotech About to Go from Goat to Hero?

I've previously written that I've been poised to buy biotechs again, but that I wanted to see some more evidence of price confirmation. After all, this volatile space has punished anticipatory traders so far this year. (Sometimes I agree with my Rea...

2 Big -- and Mispriced -- Biotech Stocks

2 Big -- and Mispriced -- Biotech Stocks

AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.

2 Portfolios for the Fundamentally Sound

2 Portfolios for the Fundamentally Sound

We offer 10 names each in the Opportunistic Value portfolio and the Income-Oriented portfolio.

My Takeaways and Observations

Did I mention that the market has no memory from day to day? It was a busy short-side day for me today. Disney (DIS) -- why the mouse is no longing roaring.   On management B.S.  Macy's (M).   Sears (SHLD) is the elephant in the room and a possible ...

Biotech Gets a Lifeline

Biotech Gets a Lifeline

Solid earnings and the start of some M&A activity may be just what this sector needs to rise.

Biotech Is Ripe for M&A: Analysts

After an asset price drop, large pharmaceutical companies are looking for strategic purchases.

2Q Is Going to Be Just as Dismal

2Q Is Going to Be Just as Dismal

Ramp up cash allocation, and get ready for a depressing second quarter.

Cramer: Apple -- Stay or Go?

Cramer: Apple -- Stay or Go?

And if you go, what would you pay to get back in?